Drug Trial Radar · NCT05983939
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jun 26, 2023
Primary completion
Feb 1, 2024
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- Contineum TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Safety will be assessed by periodic measurement of vital signs, physical examinations, electrocardiograms, blood laboratory analyses and occurrence of adverse events (AE).
Conditions
- Multiple Sclerosis
Interventions
PIPE-791Drug
Single and multiple ascending oral doses of PIPE-791 tablets.
PlaceboDrug
Single and multiple ascending oral doses of matching placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Treatment-Emergent Adverse Events (TEAE)Time frame: Baseline to 14 days post dosing for SAD cohorts and 14 days post dosing for MAD cohorts
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Worldwide Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.